PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
暂无分享,去创建一个
Razelle Kurzrock | David S. Hong | Rajyalakshmi Luthra | R. Kurzrock | F. Janku | A. Naing | D. Hong | J. Wheler | S. Piha-Paul | A. Tsimberidou | S. Moulder | Xuemei Wang | R. Luthra | G. Falchook | S. Fu | Filip Janku | J. Moroney | Siqing Fu | Aung Naing | I. Garrido-Laguna | Stacy L. Moulder | Jennifer J. Wheler | Ignacio Garrido-Laguna | Xuemei Wang | Gerald S. Falchook | Apostolia M. Tsimberidou | Sarina A. Piha-Paul | John W. Moroney
[1] R. Kurzrock,et al. Uncommon tumors and exceptional therapies: paradox or paradigm? , 2007, Molecular Cancer Therapeutics.
[2] Razelle Kurzrock,et al. Risks and benefits of phase 1 oncology trials, revisited. , 2005, The New England journal of medicine.
[3] Massimo Libra,et al. PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches , 2009, Cell cycle.
[4] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[5] M. Ratain,et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[7] R. Kurzrock,et al. Targeted therapy in non-small-cell lung cancer—is it becoming a reality? , 2011, Nature Reviews Clinical Oncology.
[8] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[9] A. Lash,et al. Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.
[10] 三宅 貴仁. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences , 2008 .
[11] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[12] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[13] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[14] Z. Jehan,et al. PIK3CA alterations in Middle Eastern ovarian cancers , 2009, Molecular Cancer.
[15] R. Kurzrock,et al. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. , 2010 .
[16] Peter Kraft,et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[18] H. Koeppen,et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples , 2009, Modern Pathology.
[19] R. Kurzrock,et al. Phosphatase and tensin homologue (PTEN) loss and response to phase I trials targeting PI3K/AKT/mTOR pathway in patients with advanced cancer. , 2010 .
[20] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[21] R. Kurzrock,et al. Abstract B247: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors , 2009 .
[22] Seiichiro Yamamoto,et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. , 2005, The New England journal of medicine.
[23] Spiros Manolidis,et al. PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma , 2006, Clinical Cancer Research.
[24] Razelle Kurzrock,et al. Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse , 2010, Clinical Cancer Research.
[25] R. Kurzrock,et al. Targeted therapy in non-small-cell lung cancer—is it becoming a reality? , 2010, Nature Reviews Clinical Oncology.
[26] R. Kurzrock,et al. Cancer: the road to Amiens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[28] Wayne A. Phillips,et al. Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.
[29] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[30] Frank McCormick,et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.
[31] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[32] G. Mills,et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. , 2009, Cancer research.
[33] Mingming Jia,et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..